About DRG Epidemiology
DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.
All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.
All epidemiological forecasts may be supplemented with custom deliverables, such as:
- Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
- Customized and interactive patient flow models or additional subpopulations or metrics
- Expanded geographical coverage or extended forecast periods beyond those available
Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.
The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.
For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.
All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.
- Asia Pacific Data
- Key Findings
- Incidence of Pancreatic Cancer per 100,000 per Year Among People of All Ages in 2017 and 2027
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Pancreatic Cancer over the Next Ten Years
- Analysis of the Incident Cases of Pancreatic Cancer in 2017 by Stage at Diagnosis
- Epidemiology Data
- Newly Diagnosed Incidence
- Stage Distribution
- Resection Status
- Recurrent Incidence
- Diagnosed Prevalence
- Drug-Treatable Populations
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Nicole Zhang, MPH
Nicole Zhang is an Epidemiologist at Decision Resources Group. She focuses on the epidemiology of oncology and cardiovascular disorders. She holds an from Tufts Medical School where she specialized in epidemiology and biostatistics. She also holds a in Chemistry and Statistics from Mount Holyoke College. Prior to joining Decision Resources, she worked as a research analyst at Massachusetts General Hospital where she independently managed data from food information survey conducted in Chelsea, MA. She has also worked at Massachusetts Department of Public Health where she conducted secondary research in the fields of gestational diabetes.